A number of other research analysts have also commented on LIVN. Berenberg Bank reissued a buy rating and set a $70.00 target price on shares of LivaNova in a report on Friday, August 11th. WBB Securities lowered LivaNova from a hold rating to a sell rating and set a $50.00 target price on the stock. in a report on Tuesday, August 15th. Jefferies Group started coverage on LivaNova in a report on Friday, September 8th. They set a buy rating and a $76.00 target price on the stock. Piper Jaffray Companies reissued an overweight rating and set a $75.00 target price on shares of LivaNova in a report on Tuesday, September 12th. Finally, Canaccord Genuity reissued a hold rating and set a $71.00 target price on shares of LivaNova in a report on Wednesday, September 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $79.71.
LivaNova (NASDAQ LIVN) traded up $0.90 on Tuesday, reaching $83.64. The company had a trading volume of 488,900 shares, compared to its average volume of 392,163. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04. LivaNova has a twelve month low of $44.58 and a twelve month high of $88.56. The company has a market cap of $3,989.02, a PE ratio of 23.84, a PEG ratio of 2.48 and a beta of 0.61.
In related news, Director Alfred J. Novak sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total value of $171,540.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $74.58, for a total value of $74,580.00. The disclosure for this sale can be found here. Insiders sold 6,830 shares of company stock worth $557,100 over the last ninety days. 0.28% of the stock is currently owned by insiders.
A number of institutional investors have recently bought and sold shares of LIVN. Vanguard Group Inc. raised its position in LivaNova by 4.5% in the first quarter. Vanguard Group Inc. now owns 777,356 shares of the company’s stock valued at $38,098,000 after purchasing an additional 33,645 shares during the last quarter. Bank of Montreal Can raised its position in LivaNova by 18,000.8% in the second quarter. Bank of Montreal Can now owns 42,899 shares of the company’s stock valued at $2,625,000 after purchasing an additional 42,662 shares during the last quarter. Russell Investments Group Ltd. bought a new position in LivaNova in the second quarter valued at about $957,000. Strs Ohio bought a new position in shares of LivaNova during the second quarter worth about $673,000. Finally, Bessemer Group Inc. bought a new position in shares of LivaNova during the second quarter worth about $220,000. Hedge funds and other institutional investors own 86.07% of the company’s stock.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.